Tricida (TCDA) Misses Q1 EPS by 9c

Tricida (NASDAQ: TCDA) reported Q1 EPS of ($1.49), $0.09 worse than the analyst estimate of ($1.40).

“COVID-19 has been particularly harmful to patients with chronic kidney disease who are already facing many serious comorbidities,” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer and President. “We are sensitive to the needs of these patients and the health care providers who serve them. Even against the backdrop of a pandemic, we remain committed to truly make a difference in these patients’ lives and potentially slow the inevitable progression of their underlying kidney disease.”

For earnings history and earnings-related data on Tricida (TCDA) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• First US Bancshares, Inc. (FUSB) Reports Q1 EPS of $0.34
• Ternium SA (TX) Tops Q1 EPS by 17c